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Influenza virus is a negative segmented RNA virus without DNA intermediate. This makes
it safer as a vaccine delivery vector than most DNA viruses that have potential to inte-
grate their genetic elements into host genomes. In this study, we developed a universal
influenza viral vector, expressing the receptor binding subdomain of botulinum neurotoxin
A (BoNT/A). We tested the growth characters of the engineered influenza virus in chicken
eggs and Madin–Darby canine kidney epithelial cells (MDCK), and showed that it can be
produced to a titer of 5×106 plaque forming unites/ml in chicken eggs and MDCK cells.
Subsequently, mice intranasally vaccinated with the engineered influenza virus conferred
protection against challenge with lethal doses of active BoNT/A toxin and influenza virus.
Our results demonstrated the feasibility to develop a dual purpose nasal vaccine against
both botulism and influenza.
Keywords: botulinum neurotoxin, influenza, intranasal vaccination, protective immunity, recombinant
influenza vector
INTRODUCTION
Influenza A virus is a member of family orthomyxoviridae, which
contains a segmented RNA genome. With the elucidation of repli-
cation mechanism of influenza virus, generation of influenza virus
from DNA became feasible and extended the research of influenza
dramatically. The most important application of this system is
creation of live-attenuated vaccine or the generation of influenza
vector to express foreign antigens (1–3). Engineered influenza
viruses expressing foreign antigens have successfully induced a
vigorous immune response in mice by the intranasal immuniza-
tion (4–6). In early stage of influenza virus vector development,
influenza virus non-structural gene (NS) segment was engineered
to express foreign antigen with deletion of the nuclear export pro-
tein (NEP), formally referred to as NS2 (7–11). With the finding
of 2A cleavage sequence of picornavirus, NS gene segment was
modified with multi-cistronic sites. It enlarged the containment
of foreign gene, kept a high growth of engineered influenza virus,
and enhanced genetic stability (7, 12).
Botulinum neurotoxins (BoNTs, A–H) are the most poisonous
substances known in nature. They may be used as bioterrorism
agents or in biological warfare. Currently, there is no FDA licensed
botulism vaccine available for public use. Natural BoNT is divided
into a light chain (L) and a heavy chain (H) (13). L chain is a
globular protein with Zn+-metalloprotease activity (14). H chain
is divided into N-terminal translocation domain and C-terminal
receptor binding domain (HC50), which consists of N-terminus
without assigned function and C-terminus with receptor binding
subdomain (rbsd) (15, 16). Previously, we developed an effec-
tive adenovirus-vectored vaccine expressing HC50 (17). In this
research, we created a recombinant influenza virus vector with a
2A cleavage site on NA. Subsequently, we generated an engineered
influenza virus based on H1N1 PR8 virus, expressing the trun-
cated HC50-rbsd from BoNT/A. Intranasal vaccination with this
engineered influenza virus was evaluated for protection against
lethal challenges with BoNT/A and influenza virus.
MATERIALS AND METHODS
CELL CULTURE AND ANIMAL STUDIES
Madin–Darby canine kidney epithelial cells (MDCK) were cul-
tured in modified Eagle’s medium with 10% fetal calf serum.
293T cells were cultured in Dulbecco’s modified eagle’s medium
(DMEM) with 10% fetal calf serum. BALB/c mice were purchased
from the Jackson Laboratories (Bar Harbor, ME, USA). Animal
experimental protocol (protocol number is 10020) was approved
by the Institutional Animal Care and Use Committee at Texas Tech
University Health Sciences Center, and carried out in accordance
with the US Public Health Service Guide for the Care and Use of
Laboratory Animals (NRC Publication, 8th ed.) and other related
federal statutes and regulations of the Animal Welfare Act. MLD50
were determined by Reed–Muench method (18).
GENERATION OF ENGINEERED INFLUENZA VIRUSES
First, we synthesized a gene segment coding 2A peptide followed
by a multiple cloning site (mcs) (19). Then, it was linked with
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185 bp of C terminal for packaging signals of NA gene segment
by overlap PCR. Subsequently, the N-terminal non-coding region
with ORF of NA gene segment was linked with the above gene
segment by overlap PCR (Figure 1A). Finally, full-length PCR
product was inserted into pHW-2000. New plasmid was desig-
nated pHW-NA-mcs. Synthesized human-codon-optimized gene
segment of BoNT/A-HC50-rbsd (amino acid 1088-1293, Gen-
Bank: CAL82360.1), was inserted into pHW-NA-mcs, and the
plasmid was named pHW-NA-B/A-rbsd. Engineered influenza
viruses using PR8 influenza virus as backbone were rescued by
reverse genetics with eight plasmids (20). The wild type control
A/Puerto Rico/8/1934(H1N1) influenza virus (PR8) was produced
by similar method.
VIRAL GROWTH AND TITRATION
About 100 pfu viruses were inoculated into allantoic cavity of a 9-
day-old specific pathogen free (SPF) embryonated eggs (Charles
River, CT, USA). At 72 h post-inoculation, viruses were harvested
and titrated on monolayer MDCK cells by using the standard
plaque assay method. To measure virus growth curve, mono-
layer MDCK cells were initially infected with virus at multiplic-
ity of infection (MOI) of 0.001. After 1 h incubation, virus was
removed and MDCK cells were washed with PBS supplemented
with Ca++ and Mg++, then medium were replaced with fresh
medium supplemented with 0.2% BSA and 1µg/ml Tosyl pheny-
lalanyl chloromethyl ketone (TPCK)-trypsin. At 24, 36, 48, 60, and
72 h post-infection, virus samples were collected, respectively, and
titrated on monolayer MDCK cells in triplicate.
RT-PCR
Viral RNA was extracted from virus samples using RNeasy kit
(Qiagen, CA, USA), and subjected to the RT-PCR amplification
by using SuperScript III Reverse Transcriptase kit (Invitrogen, CA,
USA). RT-PCR products were analyzed by electrophoresis in 0.8%
agarose gel. The images were taken by VersaDoc imager (BioRad,
CA, USA).
WESTERN-BLOTTING
Madin–Darby canine kidney epithelial cells were infected with
influenza virus at MOI of 1. At 8 h post-infection, cells were
harvested and lysed. Proteins were separated on 10% SDS-PAGE
and transferred to nitrocellulose membrane. Then, membrane was
incubated with anti-BoNT/A-HC50 serum (prepared in our lab),
rabbit anti-NP polyclonal antibody (Immune-tech), and β-actin
antibody, respectively. After being washed, membrane was incu-
bated with goat anti-rabbit or -mice IgG-HRP for 1 h. Finally,
membrane was developed with chemiluminescence HRP substrate
(Takara Bio Inc.), and images were taken by using ImageQuant
Las4000 (GE Health, PA, USA).
ANIMAL EXPERIMENTS
Forty-eight (48) 6-week female BALB/c mice were divided to 8
groups. Subsequently, the mice were intranasally vaccinated with
5 pfu influenza virus. At 4 weeks post-infection, mice were boosted
with the same dose. Blood samples were collected on the days of
immunization and challenge. On day 42, mice were challenged
with 10× MLD50 BoNT/A toxin (BEI Resources, cat# NR-4529,
NIAID, NIH) or 100× MLD50 PR8 influenza virus. After being
challenged, mice were observed every day. In the BoNT/A toxin
challenged groups, data of survived mice and dead mice were
calculated. In the PR8 challenged groups, mouse weights were
recorded every day. When the mouse weight loss was >25%,
the mouse was euthanized and sacrificed according the guide of
the Institutional Animal Care and Use Committee at Texas Tech
University Health Sciences Center.
FIGURE 1 | Design and identification of influenza virus
expression of BoNT/A-rbsd. (A) (Top) Organization of the original
(wt) NA gene segment. (Middle) Organization of the modified NA
gene segment engineered with porcine teschovirus (PTV)-1 2A
cleavage site and multiple cloning site (mcs). (Bottom) Organization of
the modified NA gene segment engineered with receptor binding
subdomain of BoNT/A toxin. (B) NA gene segment amplified by
RT-PCR. (C) Receptor binding subdomain of BoNT/A toxin is
expressed in MDCK cells infected with engineered influenza virus
PR8-B/A-rbsd, as determined by Western blot.
Frontiers in Immunology | Immunotherapies and Vaccines April 2015 | Volume 6 | Article 170 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Li et al. Vaccine against botulism and influenza
ELISA
Briefly, microplates were coated with recombinant BoNT/A recep-
tor binding subdomain overnight. After antigen was removed
and plates were blocked, sera were diluted and added into each
wells, and incubated at 4oC overnight. One hundred microliters of
diluted goat anti-mouse IgG-Fc antibody conjugated to alkaline-
phosphtase were added into each well and incubated for 1 h.
Subsequently, plates were washed and pNPP substrate was added
and incubated for 20 min. After sufficient color development, stop
solution was added into each well. Finally, the plates were read in
the Gene5 microplate reader (BioTek).
STATISTICAL ANALYSIS
Comparison between virus titers was performed by using t
test calculator (http://www.graphpad.com/quickcalcs/ttest1.cfm).
P values<0.05 were considered to be significant difference. Com-
parisons between vaccinated groups were performed by using a
non-parametric one-ways ANOVA with the Tukey multiple com-
parison test and Fisher’s exact, and survival dates were analyzed
by using the log-rank test. The analyses were performed by using
GraphPad Prism version 5.0 for Windows (GrahPad Software).
P values <0.05 were considered to be significant difference.
RESULTS
RESCUE OF ENGINEERED INFLUENZA VIRUSES
At first, NA gene segment was engineered by inserting a multi-
cloning site with a 2A cleavage site. Then a universal replication-
competent influenza viral vector was rescued. To demonstrate the
use of this universal influenza viral vector, a 618 bp gene segment
of BoNT/A HC50-rbsd was inserted into engineered NA gene seg-
ment. An engineered influenza virus carrying target gene segment
was rescued, purified, and propagated in embryonated chicken
eggs. The rescued viruses were named PR8-wt, PR8-mcs, PR8-
B/A-rbsd, respectively. Then, viruses propagated in embryonated
chicken eggs were harvested, aliquoted, and stored at −80°C for
subsequent use.
CONFIRMATION OF RECOMBINANT INFLUENZA VIRUS
To confirm rescued influenza viruses carrying anticipated NA gene
segment, viral RNA was extracted, and NA gene segments were
amplified. Results in Figure 1B showed wild type NA gene or engi-
neered NA gene segments were enclosed in the rescued influenza
virus. Furthermore, expression of BoNT/A receptor binding sub-
domain was confirmed by western-blotting. Figure 1C shows the
correct size of BoNT/A HC50-rbsd is around 26 kDa.
GROWTH CHARACTERISTICS OF ENGINEERED INFLUENZA VIRUSES
Plaque assay on MDCK cells was performed to analyze the growth
characteristics of engineered influenza viruses. In Figure 2A,
plaques formed by engineered influenza virus are smaller than
that formed by wild type PR8. Furthermore, the growth characters
were tested in MDCK cells and eggs. The results in Figures 2B,C
showed that titers of engineered influenza viruses are lower than
those of wild type. It suggested that engineering NA gene was
inhibitory to replication of influenza virus. However, the engi-
neered influenza virus propagated with reasonable titers in MDCK
cells and embryonated chicken eggs. The titers could reach to
5× 106 pfu/ml.
HUMORAL IMMUNE RESPONSE AND PROTECTION STIMULATED BY
ENGINEERED INFLUENZA VIRUS
In Figure 3A, results showed that intranasal vaccination with the
recombinant influenza virus PR8-B/A-rbsd stimulated significant
FIGURE 2 | Growth characters of wild type and engineered PR8 influenza viruses. (A) Plaque formed by infection with wild type and engineered PR8
influenza viruses on monolayer MDCK cells. (B) Virus growth character in embryonated chicken eggs (**P< 0.05). (C) Virus growth curves on monolayer
MDCK cells.
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FIGURE 3 | Intranasal vaccination with the engineered influenza virus
expressing BoNT/A HC50-rbsd conferred protection against BoNT/A and
influenza virus infection. Mice were intranasally inoculated with 5 pfu of
PR8-B/A-rbsd virus at weeks 0 and 4, and challenged with 10×MLD50 BoNT/A
toxin or 100×MLD50 PR8 influenza virus on day 42. (A) Vaccination with
PR8-B/A-rbsd virus-induced antibody response against receptor binding
subdomain of BoNT/A toxin (**P<0.05 compared with PBS group or PR8-wt
group). (B) Vaccination with PR8-B/A-rbsd conferred protection against lethal
challenge with BoNT/A toxin. (C) Vaccination elicited antibody response
against HA of PR8 influenza virus (*P>0.05 compared with PR8-wt group).
(D) Vaccination provided protection against lethal infection with PR influenza
viruses (n=8 for each group).
humoral immune response against BoNT/A toxin receptor bind-
ing subdomain compared with wild type influenza virus PR8.
In Figure 3B, results showed that vaccination with PR8-B/A-
rbsd provided protection against challenge with 10× MLD50
active BoNT/A toxin. We also tested whether immunization
with PR8-B/A-rbsd induced adaptive immunity against influenza
virus infection. We tested the humoral immune response against
influenza virus by using hemagglutination inhibition (HAI)
method and challenged immunized mice with 100×MLD50 PR8
influenza virus. In Figures 3C,D, the results showed vaccination
with PR8-B/A-srbd stimulated potent humoral immune response,
and resulted in high HAI titers and protection against challenge
with lethal PR8 influenza virus.
DISCUSSION
Influenza virus has plenty of advantages that make it worthy of
consideration for use as a viral vector for pathogens that are
problematic to vaccine development. There are well-established
protocols for large-scale production of both live and inactivated
influenza viruses, and live influenza vaccines have shown to elicit
strong T cell immune response to stimulate mucosal and sys-
temic responses (21, 22). Live-attenuated influenza virus may
be the suitable virus vector to express foreign antigen as dual
purpose vaccine. As depicted previously, there are several publica-
tions showed influenza virus could engineered to express foreign
antigen; however, there is no research using influenza virus as
vector to express antigen of botulism. In this research, we used
mouse-adapted influenza virus as vector to express the receptor
binding subdomain of BoNT/A toxin. In animal experiments, the
engineered influenza viruses still have certain degree of path-
ogenicity in mouse (MLD50 is 5,000 pfu, data not shown). In
the future, we will use cold-adapted influenza viruses as vectors,
because research has shown cold-adapted influenza virus is much
safer than seasonal one (8, 23).
Botulinum neurotoxins are the most poisonous substances in
the nature and potential bioterrorism agents. With the advantage
of molecular technology, identification of non-toxic domains of
BoNT toxin provides a useful method to develop a promising vac-
cine for botulism. In this research, our results showed that the
smaller receptor binding subdomain of BoNT/A toxin is an effec-
tive antigen to stimulate humoral immune response. Additional
research in this direction may lead to a multivalent vaccine against
all types of BoNTs using the smaller antigen (HC50-rbsd) instead
of HC50 (17) from each serotype. Data from this research demon-
strated the possibility to develop a dual protective vaccine against
both botulism and influenza. In this research, PR8 influenza virus
is an old laboratory-adapted influenza virus. Maybe it is not suit-
able to be as human influenza vaccine. It just provides a research
platform. In further research, cold-adapted or attenuated sea-
sonal or pandemic influenza viruses will be recruited to provide a
viable vaccine for bio-defense against BoNTs and for public health
emergency against potential pandemic influenza.
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